Financial Performance Overview

Emcure Pharmaceuticals Limited reported strong financial results for FY 2025-26 with consolidated revenue from operations growing 16.6% to INR 92,035.40 Mn from INR 78,959.97 Mn in the previous year. Profit after tax increased 33.1% to INR 9,412.69 Mn from INR 7,074.67 Mn, while EBITDA grew 21.8% to INR 17,886 Mn with margins improving 80 bps to 19.4%. The company crossed the significant milestone of USD 1 Bn in revenue for the first time.

Operational and Business Highlights

Domestic business contributed INR 40,270 Mn (10% growth, 44% of total revenue) while international business grew 22.2% to INR 51,766 Mn (56% of total revenue), with Europe (INR 18,498 Mn, 25.5% growth), Canada (INR 14,869 Mn, 18.7% growth), and Rest of World (INR 18,399 Mn, 21.8% growth) showing strong performance. The company maintained 32 large brands above INR 500 Mn revenue and achieved ~60%+ chronic mix in domestic business.

Strategic Initiatives and Partnerships

Emcure completed several strategic moves including the acquisition of the remaining 20.42% minority stake in Zuventus Healthcare Limited for INR 7,248.94 Mn, making it a wholly-owned subsidiary. The company formed significant partnerships with Novo Nordisk for exclusive distribution of Poviztra® (semaglutide) for obesity, strengthened its nephrology portfolio with Roche, and expanded its Sanofi partnership to include oral anti-diabetic brands Amaryl and Cetapin.

Capital Markets and Corporate Actions

The company successfully completed its INR 8,000 Mn IPO in FY25, utilizing proceeds for debt repayment (INR 6,000 Mn) and general corporate purposes (INR 1,588.64 Mn). The Board recommended a final dividend of INR 3.60 per equity share (36%) for FY26, with record date set for September 4, 2026. Key financial ratios showed significant improvement with Return on Equity at 21.77% (up from 12.79%) and Debt Service Coverage Ratio at 2.14 (up from 0.47).

R&D and Innovation

R&D investment reached INR 3,835 Mn (4.2% of revenue, 50 bps increase YoY) with focus on complex injectables, biologics, novel drug delivery systems, and antibody-drug conjugates. Key pipeline achievements included launch of Liposomal Amphotericin B in Europe, CDSCO endorsement for Bevacizumab ophthalmic biosimilar, and participation as one of six global voluntary licensees for Gilead's Lenacapavir HIV treatment.

ESG and Compliance Performance

The company demonstrated strong ESG performance with 64.7% renewable power in total energy mix, zero cybersecurity breaches, and zero confirmed corruption cases. CSR spend amounted to INR 109 Mn while safety incidents were minimal (3 incidents including contract workforce). The company received various government grants including INR 540 Mn under the Production Linked Incentive scheme.

Corporate Governance and AGM

Emcure maintained strong corporate governance with a 10-member Board (20% women representation) and 11,686 employees. The 45th Annual General Meeting is scheduled for September 21, 2026, to be held virtually, where shareholders will vote on re-appointment of Satish Mehta as MD & CEO, Mukund Gurjar as Whole-time Director, and appointment of Raghu Kumar as Independent Director, alongside dividend declaration and financial statement adoption.

Subsequent Events

Post year-end, Mantra Pharma Inc. (a step-down subsidiary) acquired 100% of Cutimed Inc. for up to CAD 5.05 Mn (INR 337.54 Mn) to strengthen the Group's Canadian dermatological and cosmetic portfolio, which will be reflected in FY27 financial statements.